CCND1 and melanoma: Using data generated from melanoma tissue samples from Chinese patients, as well as the TCGA, and MSKCC databases, we have shown the following: 1) melanoma with CCND1 amplification is an independent genomic subtype, 2) CCND1 amplification is associated with poor prognosis in unselected melanoma patients as well as in melanoma patients treated with ICIs, and this association is stronger among patients with a high TMB, 3) CCND1 amplification is related to an immunosuppressive TME, down-regulation of angiogenesis, and increased oxidative metabolism and lipid metabolism.